Table 1.

Patient and disease characteristics and comorbidity at baseline

CharacteristicTN ≥65 years 420 (n = 27), %R/R 420 (n = 67), %
Median age, years (range)71 (65–84)66 (37–82)
 ≥70 years74%36%
ECOG PS
 078%40%
 122%57%
 20%3%
Rai stage
 0–II41%45%
 III–IV56%51%
 Unknown4%4%
Bulky nodes
 ≥5 cm11%52%
 ≥10 cm0%9%
β2-Microglobulin level >3 mg/L30%42%
FISH cytogenetic abnormalities
 Del17p7%34%
 Del11q0%33%
Any cytopenia67%54%
Median ANC, 109/L (range)4 (0–19)2.5 (0–14)
 ≤1.5 × 109/L4%27%
Median hemoglobin, g/L (range)122 (77–157)118 (66–176)
 ≤110 g/L37%33%
Median platelets, 109/L (range)113 (32–217)107 (29–310)
 ≤100 × 109/L41%39%
Median CrCl rate, mL/minute (range)67 (31–114)81 (36–213)
 ≤60 mL/minute30%19%
Median prior therapies, n (range)4 (1–12)
 1–231%
 313%
 ≥455%
Type of prior systemic therapy
 Chemotherapy100%
 Nucleoside analogue94%
 Alkylator (including bendamustine)90%
 Any anti-CD20–based therapy99%
 Anti-CD20–based chemoimmunotherapy97%
 Anti-CD52–based therapy (alemtuzumab)24%
 Idelalisib6%
  • Abbreviations: ANC, absolute neutrophil count; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; R/R, relapsed/refractory.